17.75
price down icon1.93%   -0.35
after-market 시간 외 거래: 16.87 -0.88 -4.96%
loading
전일 마감가:
$18.10
열려 있는:
$18.05
하루 거래량:
863.48K
Relative Volume:
0.50
시가총액:
$1.39B
수익:
$198.84M
순이익/손실:
$-111.40M
주가수익비율:
-3.927
EPS:
-4.52
순현금흐름:
$-322.28M
1주 성능:
-3.38%
1개월 성능:
+16.55%
6개월 성능:
+183.55%
1년 성능:
+154.66%
1일 변동 폭
Value
$17.32
$18.10
1주일 범위
Value
$16.77
$18.90
52주 변동 폭
Value
$5.12
$19.25

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
명칭
Travere Therapeutics Inc
Name
전화
888-969-7879
Name
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Name
직원
380
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
TVTX's Discussions on Twitter

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-03-27 다운그레이드 Guggenheim Buy → Neutral
2023-12-05 업그레이드 Citigroup Neutral → Buy
2023-11-20 개시 Citigroup Neutral
2023-09-22 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-09-21 다운그레이드 William Blair Outperform → Mkt Perform
2023-09-06 재개 Evercore ISI Outperform
2023-07-21 개시 JP Morgan Overweight
2023-06-07 재개 Piper Sandler Neutral
2023-05-22 개시 TD Cowen Outperform
2023-05-05 업그레이드 Bryan Garnier Sell → Neutral
2023-03-01 개시 Guggenheim Buy
2023-02-21 업그레이드 Wedbush Neutral → Outperform
2022-12-14 개시 Stifel Hold
2022-12-05 개시 Wells Fargo Overweight
2022-09-21 개시 Bryan Garnier Sell
2022-07-14 재개 Canaccord Genuity Buy
2022-03-31 개시 Piper Sandler Overweight
2022-02-28 개시 H.C. Wainwright Buy
2021-05-26 다운그레이드 Wedbush Outperform → Neutral
모두보기

Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스

pulisher
04:19 AM

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

04:19 AM
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere: Q3 Earnings Snapshot - The Washington Post

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 29, 2024

Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance

Oct 28, 2024
pulisher
Oct 27, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Oct 27, 2024
pulisher
Oct 26, 2024

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times

Oct 26, 2024
pulisher
Oct 25, 2024

TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail

Oct 25, 2024
pulisher
Oct 25, 2024

(TVTX) Trading Report - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines

Oct 24, 2024
pulisher
Oct 24, 2024

Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance

Oct 24, 2024
pulisher
Oct 23, 2024

Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN

Oct 23, 2024
pulisher
Oct 21, 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada

Oct 21, 2024
pulisher
Oct 18, 2024

State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com

Oct 18, 2024
pulisher
Oct 18, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia

Oct 18, 2024
pulisher
Oct 17, 2024

Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan

Oct 17, 2024
pulisher
Oct 17, 2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire

Oct 17, 2024
pulisher
Oct 16, 2024

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga

Oct 16, 2024
pulisher
Oct 16, 2024

Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews

Oct 15, 2024

Travere Therapeutics Inc (TVTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Travere Therapeutics Inc 주식 (TVTX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
LYONS GARY A
Director
Oct 04 '24
Sale
14.73
40,000
589,101
51,000
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):